Clinical Trials in Adjuvant IO Therapy for RCC

Video

Tian Zhang, MD, explains whether recent data from ESMO 2022 has changed their approach to adjuvant immune therapy in advanced RCC.

Related Videos
Alexander I. Spira, MD, PhD, FACP, an expert on lung cancer
Alexander I. Spira, MD, PhD, FACP, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Related Content
Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

May 13th 2023
Article

A panel of experts discuss the updated results of the phase 3 CLEAR trial presented at the 2022 International Kidney Cancer Symposium.

Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma

Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma

April 21st 2021
Article

This article reviews the results of the phase 3 KEYNOTE-581/CLEAR trial and features expert insights from trial investigators, Robert J. Motzer, MD, and Toni Choueiri, MD.